Fig. 1From: Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health AdministrationAlgorithm for intended use of EGFR and proteomic testing in NSCLC patients. For clarity, various algorithms of chemotherapy and targeted treatments other than erlotinib were not includedBack to article page